The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

Tue, 25th Jan 2022 19:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cordiant Digital Infrastructure Ltd - investment firm focused on digital infrastructure assets - Raises GBP200 million from placing of 188.7 million shares at 106 pence each. "The net proceeds of the placing will be used to fully finance the acquisition of Emitel," Cordiant says. Emitel is a multi-asset digital infrastructure business based in Warsaw.

----------

Home REIT PLC - homeless accommodation investor - Deploys remaining GBP55.1 million from GBP350 million fundraise. Acquires 240 additional properties, located across England and providing 880 beds. Bring total portfolio to 7,953. "Each of the properties is immediately income producing and, following these transactions, the blended net initial yield of the company's portfolio is ahead of expectations," Home REIT says.

----------

Phoenix Spree Deutschland Ltd - Investor specialising in German residential real estate - Inks new EUR60 million loan facility, comprising a EUR45 million acquisition facility and EUR15 million capex facility. Matures in September 2026 and carries 1.15% over 3-month Euribor interest. In addition, refinances existing debt provided by Berliner Sparkasse. Says total value of loans which have been refinances stand at EUR49.7 million.

----------

Frontier IP Group PLC - London-based intellectual property commercialisation company - Sells 183,901 American depositary shares in portfolio firm Exscientia PLC to net USD4.0 million. Now owns 1.4 million shares in investee. "The directors of Frontier IP intend to use the net proceeds from the sale of ADSs in Exscientia for general working capital purposes and to provide further support to the group's existing portfolio companies," Frontier IP adds.

----------

Foresight Sustainable Forestry Co PLC - forestry investment trust, managed by private equity firm Foresight Group LLP - Agrees variation to deal to acquire seed assets portfolio Foresight Inheritance Tax Fund. Allocation of afforestation assets upped to 34% from 27%, closer to 40-50% target. Says Blackmead Forestry Ltd, which it has option to acquire, receives planning approval and confirmation of grant funding for Banc Farm.

----------

AIQ Ltd - Cayman Islands-based firm focused on acquiring and developing e-commerce sector businesses - Raises GBP500,000 through issue of unsecured convertible loan notes to three existing shareholders. One GBP250,000 note issued to Executive Director Li Chun Chung, who has 2.2% stake. Two GBP125,000 notes issued to Soon Beng Gee and Lee Ching Liang. Gee and Liang each own 18% stake in company. "The proceeds of the loan notes will be used for working capital purposes as well as widening the company's offer to new sectors," AIQ says.

----------

River & Mercantile Group PLC - London-based asset manager - Proposes sale of River & Mercantile LLC, its US Solutions arm, for minimum of USD8.6 million to Agilis Holding Co LLC. River has agreed to a GBP98.8 million takeover from AssetCo PLC. AssetCo's buy is contingent on River & Mercantile successfully selling its solutions business to Schroders PLC. A deal for the division was announced back in October, with Schroders set to pay GBP230 million.

----------

Atlantic Lithium Ltd - lithium-focused exploration company - Reports further results from drilling at Ewoyaa lithium project in Ghana. Says second highest metal content drill intersection returned to date. "Further infill drilling results continue to confirm grade and continuity across the Ewoyaa deposits," Atlantic Lithium says.

----------

IOG PLC - London-based gas and infrastructure operator with projects in the North Sea - Says Bacton onshore terminal "now 93% complete". Chief Executive Andrew Hockey says: "Although it is very frustrating that it has been slower than planned, we are making every effort with the terminal operator Perenco to facilitate the fastest possible resolution. An expanded team is working days and nights aiming to be ready for back-gassing in mid-February, with First Gas expected approximately a week later." Eyeing new location for drilling rig at Southwark asset. Says total phase 1 capital expenditure to exceed GBP305.5 million field development plan budget by between 20% to 25%. "As a prudent additional measure, the company also recently signed a EUR5 million working capital facility with a recognised international bank. Meanwhile, despite recent volatility, the UK NBP gas forward curve currently remains significantly above its long-term historical annual average," IOG says.

----------

Galantas Gold Corp - Northern Ireland-focused gold producer based in Toronto - Enters into USD1.1 million loan agreement with Ocean Partners UK Ltd. Loan is payable six moths from date of issue and bears 10% annual interest. "The loan is to be used for further development of the Omagh Gold project in Northern Ireland and working capital," Galantas says.

----------

Caspian Sunrise PLC - Kazakhstan-focused oil & gas exploration and production company - Reports inital output from Deep Well A8 at BNG area. Output on 2021 was 533,857 barrels at the average rate of 1,462 bopd. "Production for sale in January 2022 is expected to be approximately 65,000 barrels," Caspain adds.

----------

Trinity Exploration & Production PLC - oil exploration company focused on Trinidad & Tobago - Says fourth quarter output average 3,103 bopd, up from 3,018 in third quarter. Average for year is 3,069 bopd, in line with guidance provided at start of 2021.

----------

President Energy PLC - Leeds-based oil & gas company focused on Latin America - Says well DP-2001 at the Puesto Guardian, Argentina, has been successfully tested. Notes "oil to surface from the two expected formation intervals that are also flowing in other parts of the Dos Puntitas field". Well to place onstream in one week. Says further analysis of well DP-2003 logs suggest potential, including in deeper interval drilled below original depth. "Whilst it serves no purpose to speculate at this stage as the company only has electric and mud log analysis with petrophysical review, the workover rig currently finishing DP-2001 will be mobilised this coming week to DP-2003 to conduct flow tests. During that time the drilling rig will be temporarily laid down in an adjacent location in the field," President says. Adds there is a further well to drill at Puesto Guardian Concession.

----------

Artemis Resources Ltd - Perth-based miner with gold, copper and cobalt projects in Pilbara region of Western Australia - Raises GBP5 million from placing of 133.3 million shares at 3.75 pence each. Artemis on Monday announced plans to list on AIM on February 7.

----------

N4 Pharma PLC - Derby, England-based pharmaceutical company - Says studies conducted with Nanomerics to evaluate Nuvec show treatment "demonstrated a significant inhibition of tumour growth derived from a human cell line". As a result of promising findings, N4 begins work with Medicines Discovery Catapult to identify suitable loads to add to Nuvec to take to clinic.

----------

Intelligent Ultrasound Group PLC - Cardiff, Wales-based artificial intelligence ultrasound software firm - Signs extension to women's healthcare AI agreement with GE Healthcare, part of General Electric Co. "Although the terms of the agreement and the timings of the related product launch are undisclosed, this supplementary product line is expected to support the growth of the group's royalty revenues in the longer term," company says.

----------

Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems - Updates on ongoing commercial trials. Says some of 2021 numerous trials leading to commercial order requests. Company says: "It is expected that the number of orders will increase during 2022-2023, some leading to further partnerships and others moving into the next stage of the trial," Graft Polymer says. On patents, Graft notes request P-2021106347 approved in Russia and Slovenia. "The patent application, which relates to core technologies included in Graft Polymer's proprietary drug delivery system, focuses on smart nanostructured materials to deliver drugs to target sites with the aim of reducing dosage frequency and mitigate the side effects experienced with traditional therapies," Graft explains.

----------

Northcoders Group PLC - Manchester-based training programmes for software coding - Says underlying performance was in line with expectations in 2021. Non-underlying costs to be lower than forecast so reported results to top market expectations. Says revenue visibility for 2022 stands at just over GBP3 million. "As the national reach of Northcoders has expanded, the group's Apprenticeship division also delivered contracts across the breadth of England. An increasing number of large employers, such as online fashion retailer, Pretty Little Thing, and logistics company, Hermes, are seeing the benefit of engaging with Northcoders to deliver apprenticeship courses on their behalf. The group has also launched its new apprenticeship 'hire to train' programme which is proving to be very popular with both corporates and individuals alike," Northcoders says.

----------

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Says revenue and Ebitda to be in line with expectations for 2021. "In 2021, we delivered a financial performance in line with expectations, excluding our ongoing dispute with the DHSC. This highlighted the agility of the company to rapidly respond to the changing marketplace for our products, with a noticeable increase in demand from the private market for Covid-19 testing in travel, sport, film, media, and workplace settings," CEO David Allmond says. Says underlying revenue meets guidance of "approximately GBP100 million". Underlying revenue for 2021 is GBP95.8 million, down from GBP277.2 million in 2020. Ebitda before exceptionals down to GBP36.0 million from GBP176.1 million.

----------

EKF Diagnostics Holdings PLC - Cardiff-based diagnostics and central laboratory assay maker - Says performance in 2021 was "strong", with adjusted earnings before interest, tax, depreciation and amortisation ahead of market expectations. "Trading in EKF's core business in the final quarter continued to be robust and ongoing demand for sample collection kits and testing remained strong through to the end of the year. The group announces that core business revenues grew over 13% compared with the previous financial year," EKF says.

----------

tinyBuild Inc - video games publisher and developer - Says performance in second half of 2021 topped expectations, helped by contribution from new acquisitions topping forecasts. "Overall, FY 2021 saw a substantial easing of restrictions related to Covid-19, with expectations that video games sales may be negatively impacted. Conversely, tinyBuild performed strongly in the second half of 2021, both in terms of back catalogue and new titles," tinyBuild says. "Early indicators of positive consumer traction across the company's pipeline, including Hello Neighbor 2, are very encouraging and we look ahead to FY 2022 with confidence."

----------

Sopheon PLC - enterprise software provider - Expects 2021 revenue of USD34 million, up from USD30 million. Says revenue visibility for 2022 stands at USD23.4 million. Adjusted Ebitda for 2021 to top USD6 million, up from USD5.9 million in 2020.

----------

DSW Capital PLC - business advisory services provider - Adds to service line with two asset-based lenders. "Hazel Lomas and Martin Ellison have over 60 years' experience between them, during which time they have worked with most of the major names in the ABL industry," DSW says. "The focus of the business is to provide asset-based lenders with specialist due diligence and risk management services across multi-asset classes to support their lending decisions and ongoing support and advice to advisers, investors and their portfolio companies."

----------

Sivota PLC - investment vehicle focused on later-stage, Israeli technology-related sectors - Enters into deal to acquire majority stake in digital marketing engagement platform Apester. "Apester will be Sivota's first acquisition, and is closely aligned with Sivota's strategic principals. Sivota is keen to leverage Apester's existing assets whilst applying forward thinking leadership and insight in order to increase value for the company's investors over time," Sivota says. To receive 14.9 million preferred seed shares for USD12 million.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.